Showing 3861-3870 of 4165 results for "".
- Second Sight Medical Products Announces Year 4 NIH Funding of its Orion Studyhttps://modernod.com/news/second-sight-medical-products-announces-year-4-nih-funding-of-its-orion-study/2480982/Second Sight Medical Products announced that the company received notice from the National Institutes of Health (NIH) of the release of year 4 funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (Orion Trial), grant 5UH3NS103442. The NIH released&n
- Xequel Bio Announces Positive Results from Phase 1b Study of iNexin, a Novel aCT1 Ophthalmic Solutionhttps://modernod.com/news/xequel-bio-announces-positive-results-from-phase-1b-study-of-inexin-a-novel-act1-ophthalmic-solution/2480963/Xequel Bio announced positive results from its phase 1b clinical trial with iNexin (aCT1 ophthalmic solution) for the treatment of corneal injury in patients with dry eye disease. The study demonstrated that iNexin was safe and well-tolerated at the doses tested, and ear
- Global Data: Increasing Cataract Surgical Rates Will Drive Artificial Lenses Market to Reach $4.7 Billion by 2030https://modernod.com/news/global-data-increasing-cataract-surgical-rates-will-drive-artificial-lenses-market-to-reach-47-billion-by-2030/2480953/The global market for IOLs is forecast by GlobalData to steadily grow from $4.3 billion in 2021 to $4.7 billion by the end of the decade. The data and analytics company notes that this growth is primarily driven by the growing capacity of many hospitals and clinics across all regions to perform m
- Formosa Pharmaceuticals and AimMax Therapeutics Announce Topline Results from CPN-301 for the Treatment of Inflammation and Pain After Cataract Surgeryhttps://modernod.com/news/formosa-pharmaceuticals-and-aimmax-therapeutics-announce-successful-topline-results-from-cpn-301-for-the-treatment-of-inflammation-and-pain-after-cataract-surgery/2480937/Formosa Pharmaceuticals and AimMax Therapeutics reported successful topline results from CPN-301, the first of two pivotal phase 3 clinical studies of APP13007, a novel ophthalmic nanosuspension formulation of a corticosteroid, clobetasol propionate(0.05%), for the treatment of inflamma
- BRIM Biotechnology Enters Trading in Taiwanhttps://modernod.com/news/brim-biotechnology-enters-otc-trading-in-taiwan/2480926/BRIM Biotechnology has entered OTC trading in Taiwan on June 23, 2022. Established in 2013, BRIM is a clinical-stage company developing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases. BRIM has several novel drug products
- Aurion Biotech Appoints Michael Goldstein, MD, as President and Chief Medical Officerhttps://modernod.com/news/aurion-biotech-appoints-dr-michael-goldstein-as-president-and-chief-medical-officer/2480904/Aurion Biotech announced it has appointed Michael Goldstein, MD, as president and chief medical officer. Dr. Goldstein will lead the company’s clinical strategy, development and operations; medical affairs; and manufacturing and quality teams for its first product candidate, a cel
- Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-tranquility2-trial-in-dry-eye-disease/2480902/Aldeyra Therapeutics announced the achievement of the primary endpoint in the phase 3 TRANQUILITY-2 clinical trial (TRANQUILITY-2) of reproxalap, an investigational new drug candidate, for the treatment of dry eye disease. Reproxalap was statistically superior to vehicle for each of the two presp
- Nicox Now Expects Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial in November 2022https://modernod.com/news/nicox-now-expects-topline-results-from-ncx-470-mont-blanc-phase-3-glaucoma-trial-in-november-2022/2480892/Nicox SA announced that it has closed screening for additional patients in its phase 3 Mont Blanc clinical trial of NCX 470 0.1% in patients with open-angle glaucoma or ocular hypertension. Therefore, the company now expects
- Orasis Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopiahttps://modernod.com/news/orasis-announces-positive-phase-3-topline-results-of-novel-eye-drop-candidate-csf-1-for-the-treatment-of-presbyopia/2480784/Orasis Pharmaceuticals announced that the phase 3 NEAR-1 and NEAR-2 clinical trials, which evaluated the efficacy and safety of CSF-1, its novel eye drop candidate, met their primary and key secondary endpoints. Additional details of these trials will be presented at future medical meet
- Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucomahttps://modernod.com/news/nicoxs-ncx-470-dolomites-phase-2-results-published-in-journal-of-glaucoma/2480758/Nicox announced that the results from its Dolomites phase 2 clinical trial of NCX 470 in patients with open-angle glaucoma or ocular hypertension have been published online by the Journal of Glaucoma. The publication “A R